Marinus Pharmaceuticals (NASDAQ:MRNS) announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.03), Bloomberg Earnings reports.
MRNS stock traded down $0.15 during midday trading on Friday, reaching $4.50. 284,946 shares of the stock were exchanged, compared to its average volume of 707,192. The firm has a market capitalization of $236.50 million, a P/E ratio of -5.00 and a beta of 3.25. Marinus Pharmaceuticals has a 52 week low of $2.36 and a 52 week high of $10.54.
A hedge fund recently raised its stake in Marinus Pharmaceuticals stock. Geode Capital Management LLC boosted its stake in shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) by 34.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 464,483 shares of the biopharmaceutical company’s stock after buying an additional 119,668 shares during the quarter. Geode Capital Management LLC owned approximately 1.15% of Marinus Pharmaceuticals worth $1,332,000 as of its most recent SEC filing. 65.39% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Rockland Register and is the sole property of of Rockland Register. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://rocklandregister.com/2019/05/18/marinus-pharmaceuticals-mrns-posts-quarterly-earnings-results-misses-expectations-by-0-03-eps.html.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Further Reading: What is diluted earnings per share (Diluted EPS)?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.